S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Heska Co. stock logo
HSKA
Heska
$119.99
$119.09
$57.83
$120.03
$1.31B1.58241,932 shsN/A
Ipsen S.A. stock logo
IPSEY
Ipsen
$28.76
+0.1%
$28.81
$26.97
$34.34
N/A0.921,646 shs1,330 shs
Neogen Co. stock logo
NEOG
Neogen
$11.61
-2.7%
$15.52
$11.51
$24.09
$2.51B1.132.13 million shs1.86 million shs
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
$17.63
$17.63
$16.04
$22.99
$3.92B1.321.24 million shs5,400 shs
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
$39.12
+2.2%
$46.48
$37.78
$95.02
$2.62B0.111.01 million shs1.11 million shs
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Heska Co. stock logo
HSKA
Heska
0.00%0.00%0.00%0.00%+2.21%
Ipsen S.A. stock logo
IPSEY
Ipsen
+0.34%-1.58%+1.63%+0.28%+1.27%
Neogen Co. stock logo
NEOG
Neogen
-1.73%-8.23%-21.05%-29.82%-28.95%
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
0.00%0.00%0.00%0.00%0.00%
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
-1.16%-10.98%-20.92%-46.37%-57.79%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Heska Co. stock logo
HSKA
Heska
N/AN/AN/AN/AN/AN/AN/AN/A
Ipsen S.A. stock logo
IPSEY
Ipsen
N/AN/AN/AN/AN/AN/AN/AN/A
Neogen Co. stock logo
NEOG
Neogen
3.2614 of 5 stars
3.31.00.00.03.03.32.5
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
4.9294 of 5 stars
4.05.00.03.81.73.32.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Heska Co. stock logo
HSKA
Heska
N/AN/AN/AN/A
Ipsen S.A. stock logo
IPSEY
Ipsen
3.00
BuyN/AN/A
Neogen Co. stock logo
NEOG
Neogen
2.50
Moderate Buy$22.5093.80% Upside
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
N/AN/AN/AN/A
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
2.00
Hold$61.6057.46% Upside

Current Analyst Ratings

Latest QDEL, NEOG, OCDX, IPSEY, and HSKA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Neogen Co. stock logo
NEOG
Neogen
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$19.00 ➝ $17.00
3/4/2024
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Sell$70.00 ➝ $42.00
2/14/2024
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
2/14/2024
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$130.00 ➝ $81.00
2/14/2024
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform
2/14/2024
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Outperform$100.00 ➝ $76.00
2/14/2024
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Underweight$66.00 ➝ $37.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Heska Co. stock logo
HSKA
Heska
$257.31M5.09$1.69 per share70.99$39.00 per share3.08
Ipsen S.A. stock logo
IPSEY
Ipsen
$3.58BN/A$3.53 per share8.15N/AN/A
Neogen Co. stock logo
NEOG
Neogen
$822.45M3.06$0.87 per share13.34$14.52 per share0.80
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
$2.04B1.92$2.28 per share7.73$1.99 per share8.86
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
$3.00B0.87$11.11 per share3.52$74.92 per share0.52

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Heska Co. stock logo
HSKA
Heska
-$19.89M-$1.93N/A83.33N/A-7.86%0.94%0.67%N/A
Ipsen S.A. stock logo
IPSEY
Ipsen
$697.43MN/A0.0010.65N/AN/AN/AN/AN/A
Neogen Co. stock logo
NEOG
Neogen
-$22.87M$0.011,162.1618.14N/A0.17%3.35%2.30%7/25/2024 (Estimated)
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
-$54.30M-$0.01N/A17.631.66-0.02%41.71%5.10%N/A
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
-$10.10M-$0.16N/A9.54N/A-0.34%5.54%3.21%5/8/2024 (Confirmed)

Latest QDEL, NEOG, OCDX, IPSEY, and HSKA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
$0.54N/A-$0.54N/AN/AN/A  
4/9/2024Q3 2024
Neogen Co. stock logo
NEOG
Neogen
$0.14$0.12-$0.02$0.25$230.01 million$228.80 million    
2/13/2024Q4 2023
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
$2.01$1.17-$0.84$2.24$796.91 million$742.60 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Heska Co. stock logo
HSKA
Heska
N/AN/AN/AN/AN/A
Ipsen S.A. stock logo
IPSEY
Ipsen
$0.230.80%N/AN/AN/A
Neogen Co. stock logo
NEOG
Neogen
N/AN/AN/AN/AN/A
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
N/AN/AN/AN/AN/A
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Heska Co. stock logo
HSKA
Heska
0.23
5.64
4.12
Ipsen S.A. stock logo
IPSEY
Ipsen
N/A
1.17
0.99
Neogen Co. stock logo
NEOG
Neogen
0.28
3.82
2.66
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
4.91
1.89
1.29
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
0.45
1.57
0.88

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Heska Co. stock logo
HSKA
Heska
99.01%
Ipsen S.A. stock logo
IPSEY
Ipsen
N/A
Neogen Co. stock logo
NEOG
Neogen
96.73%
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
N/A
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
99.00%

Insider Ownership

CompanyInsider Ownership
Heska Co. stock logo
HSKA
Heska
12.30%
Ipsen S.A. stock logo
IPSEY
Ipsen
N/A
Neogen Co. stock logo
NEOG
Neogen
0.71%
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
N/A
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
1.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Heska Co. stock logo
HSKA
Heska
80810.91 million9.57 millionNot Optionable
Ipsen S.A. stock logo
IPSEY
Ipsen
5,300N/AN/ANot Optionable
Neogen Co. stock logo
NEOG
Neogen
2,640216.61 million215.07 millionOptionable
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
4,800222.59 millionN/ANot Optionable
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
7,10066.88 million66.21 millionOptionable

QDEL, NEOG, OCDX, IPSEY, and HSKA Headlines

SourceHeadline
Investors who lost money on QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) should contact Levi & Korsinsky about pending Class Action - QDELInvestors who lost money on QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) should contact Levi & Korsinsky about pending Class Action - QDEL
accesswire.com - April 19 at 3:30 PM
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the FirmSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm
markets.businessinsider.com - April 19 at 3:28 PM
Levi & Korsinsky Notifies QuidelOrtho Corporation f/k/a Quidel Corporation Investors of a Class Action Lawsuit and Upcoming Deadline - QDELLevi & Korsinsky Notifies QuidelOrtho Corporation f/k/a Quidel Corporation Investors of a Class Action Lawsuit and Upcoming Deadline - QDEL
stockhouse.com - April 19 at 3:28 PM
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against QuidelOrtho Corporation (QDEL)Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against QuidelOrtho Corporation (QDEL)
stockhouse.com - April 19 at 3:28 PM
Class Action Filed Against QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) Seeking Recovery for Investors - Contact Levi & KorsinskyClass Action Filed Against QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) Seeking Recovery for Investors - Contact Levi & Korsinsky
accesswire.com - April 19 at 9:15 AM
William Blair Equities Analysts Raise Earnings Estimates for QuidelOrtho Co. (NASDAQ:QDEL)William Blair Equities Analysts Raise Earnings Estimates for QuidelOrtho Co. (NASDAQ:QDEL)
marketbeat.com - April 19 at 8:32 AM
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the FirmDEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm
accesswire.com - April 19 at 7:00 AM
Class Action Filed Against QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) - June 11, 2024 Deadline to Join - Contact The Gross Law FirmClass Action Filed Against QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) - June 11, 2024 Deadline to Join - Contact The Gross Law Firm
prnewswire.com - April 19 at 6:40 AM
Shareholders that lost money on QuidelOrtho Corporation f/k/a Quidel Corporation(QDEL) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreShareholders that lost money on QuidelOrtho Corporation f/k/a Quidel Corporation(QDEL) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
accesswire.com - April 19 at 5:40 AM
QuidelOrtho Corporation f/k/a Quidel Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before June 11, 2024 to Discuss Your Rights - QDELQuidelOrtho Corporation f/k/a Quidel Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before June 11, 2024 to Discuss Your Rights - QDEL
accesswire.com - April 19 at 5:40 AM
Levi & Korsinsky Notifies Shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) of a Class Action Lawsuit and an Upcoming DeadlineLevi & Korsinsky Notifies Shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) of a Class Action Lawsuit and an Upcoming Deadline
accesswire.com - April 18 at 11:15 PM
Investors in QuidelOrtho Corporation f/k/a Quidel Corporation Should Contact Levi & Korsinsky Before June 11, 2024 to Discuss Your Rights - QDELInvestors in QuidelOrtho Corporation f/k/a Quidel Corporation Should Contact Levi & Korsinsky Before June 11, 2024 to Discuss Your Rights - QDEL
accesswire.com - April 18 at 8:00 PM
QuidelOrtho Corporation f/k/a Quidel Corporation Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – QDELQuidelOrtho Corporation f/k/a Quidel Corporation Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – QDEL
accesswire.com - April 18 at 7:00 PM
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the FirmINVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm
markets.businessinsider.com - April 18 at 6:51 PM
QuidelOrtho Corporation f/k/a Quidel Corporation Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 11, 2024 to Discuss Your Rights – QDELQuidelOrtho Corporation f/k/a Quidel Corporation Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 11, 2024 to Discuss Your Rights – QDEL
accesswire.com - April 18 at 5:30 PM
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against QuidelOrtho Corporation (QDEL)Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against QuidelOrtho Corporation (QDEL)
businesswire.com - April 18 at 12:54 PM
Levi & Korsinsky Reminds QuidelOrtho Corporation f/k/a Quidel Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 11, 2024 - QDELLevi & Korsinsky Reminds QuidelOrtho Corporation f/k/a Quidel Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 11, 2024 - QDEL
accesswire.com - April 18 at 5:45 AM
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the FirmINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm
markets.businessinsider.com - April 17 at 3:30 PM
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of QuidelOrtho Corporation (QDEL) InvestorsGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of QuidelOrtho Corporation (QDEL) Investors
businesswire.com - April 17 at 2:09 PM
QDEL LAWSUIT ALERT: Levi & Korsinsky Notifies QuidelOrtho Corporation f/k/a Quidel Corporation Investors of a Class Action Lawsuit and Upcoming DeadlineQDEL LAWSUIT ALERT: Levi & Korsinsky Notifies QuidelOrtho Corporation f/k/a Quidel Corporation Investors of a Class Action Lawsuit and Upcoming Deadline
accesswire.com - April 17 at 1:15 PM
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of QuidelOrtho Corporation (QDEL) InvestorsThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of QuidelOrtho Corporation (QDEL) Investors
businesswire.com - April 17 at 12:15 PM
Levi & Korsinsky Reminds QuidelOrtho Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 11, 2024 - QDELLevi & Korsinsky Reminds QuidelOrtho Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 11, 2024 - QDEL
accesswire.com - April 17 at 10:30 AM
QuidelOrtho To Report First Quarter 2024 Financial ResultsQuidelOrtho To Report First Quarter 2024 Financial Results
finance.yahoo.com - April 17 at 9:38 AM
Benjamin Graham Detailed Fundamental Analysis - QDELBenjamin Graham Detailed Fundamental Analysis - QDEL
nasdaq.com - April 17 at 12:39 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Heska logo

Heska

NASDAQ:HSKA
Heska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell, platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was incorporated in 1988 and is based in Loveland, Colorado.
Ipsen logo

Ipsen

OTCMKTS:IPSEY
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Neogen logo

Neogen

NASDAQ:NEOG
Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods. The segment offers its products primarily to milling and grain, meat and poultry, prepared foods and ingredients, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products, and genomics testing services marketed through veterinarians, retailers, livestock producers, and animal health product distributors, for the animal safety market. The segment offers its products for companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
Ortho Clinical Diagnostics logo

Ortho Clinical Diagnostics

NASDAQ:OCDX
Ortho Clinical Diagnostics Holdings plc provides in-vitro diagnostics solutions to the clinical laboratory and transfusion medicine communities worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company is also involved in the provision of contract manufacturing and orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. Ortho Clinical Diagnostics Holdings plc was founded in 1939 and is headquartered in Raritan, New Jersey.
QuidelOrtho logo

QuidelOrtho

NASDAQ:QDEL
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.